| Title | Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000. | | Author(s) | Theilgaard SA, Buchwald C, Ingeholm P, Kornum Larsen S, Eriksen JG, Sand Hansen H | | Institution | Departments of Otolaryngology-Head & Neck Surgery, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark. sat@dadlnet.dk | | Source | Acta Otolaryngol 2003 Apr; 123(3):433-9. | | MeSH | Adolescent
Adult
Aged
Aged, 80 and over
Combined Modality Therapy
Denmark
Disease-Free Survival
Esthesioneuroblastoma, Olfactory
Female
Humans
Incidence
Male
Middle Aged
Nasal Cavity
Neoplasm Recurrence, Local
Neoplasm Staging
Nose Neoplasms
Postoperative Complications
Registries
Research Support, Non-U.S. Gov't
Retrospective Studies
Smoking
Survival Rate
| | Abstract | OBJECTIVE: A retrospective review of all diagnosed cases of esthesioneuroblastoma registered in Denmark between 1978 and 2000 was carried out in order to obtain epidemiological data and optimize national treatment guidelines.
MATERIAL AND METHODS: Forty cases were verified histologically and included in the analysis Epidemiological and histopathological data were evaluated in relation to the clinical outcome.
RESULTS: The 40 cases represent an incidence rate of 0.4 cases/million inhabitants per year. Eight (20%) patients were classified as Kadish stage A, 13 (32.5%) as stage B and 19 (47.5%) as stage C. The histopathological findings were classified according to the grading system of Hyams The median follow-up time was 2.3 years (range 0.3-11.1 years). The 5-year crude survival rate was 61%, with a median survival of 3.1 years (range 0.3-19.2 years). The 5-year disease-free survival rate was 50%, with a median survival of 1.7 years (range 0-19.2 years). Only 3 (7%) patients had positive cervical lymph nodes at presentation. A nationwide consensus regarding treatment was seen in patients classified as Kadish stages A and B. The longest duration before the first recurrence of esthesioneuroblastoma was 5(1/2) years.
CONCLUSIONS: The following therapeutic guidelines are suggested: Kadish stage A patients, surgical tumour resection and radiotherapy; Kadish stage B, surgical tumour resection and radiotherapy; Kadish stage C, surgical tumour resection via a craniofacial resection and radiotherapy combined with chemotherapy. Long-term follow-up of esthesioneuroblastoma patients is mandatory. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 12737303 |
|
